Eviplera is a combination antiretroviral medication used in the treatment of HIV (Human Immunodeficiency Virus) infection. It combines three active substances: emtricitabine, rilpivirine, and tenofovir disoproxil, each targeting the virus in different ways to prevent its replication and spread within the body. Emtricitabine and tenofovir disoproxil are both nucleoside reverse transcriptase inhibitors (NRTIs), while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). By combining these drugs into a single pill, Eviplera simplifies the treatment regimen, making it easier for patients to adhere to their medication schedule. This once-daily oral medication is generally well-tolerated and is used as part of antiretroviral therapy (ART) for adults with HIV-1 who meet certain clinical criteria.